Omnia SanaPlant Comparison
Purple coneflower vs Breckland Thyme
A side-by-side comparison of two medicinal plants — every documented constituent, action, use, safety note and cited source, assembled automatically from the Omnia Sana database.
At a glance
Purple coneflower and Breckland Thyme: they share 5 indicated uses (arthritis / joint pain, infection (general), inflammation (general), …); 2 pharmacological actions in common.
Evidence face-off — shared uses
| Condition | Purple coneflower | Breckland Thyme | Verdict |
|---|---|---|---|
| Arthritis / joint pain | 1/10 | 1/10 | Comparable evidence |
| Infection (general) | 1/10 | 1/10 | Comparable evidence |
| Inflammation (general) | 1/10 | 1/10 | Comparable evidence |
| Skin irritation | 1/10 | 1/10 | Comparable evidence |
| Wounds | 1/10 | 1/10 | Comparable evidence |
Evidence scores (1–10) are computed from the tier of each cited source. “Comparable” means the two scores are within one point. Follow a score to its detailed sources.
Key Constituents
Lipophilic alkamides are considered key immunomodulatory and anti-inflammatory constituents, particularly concentrated in the root.
Antioxidant phenolic compounds contributing to the plant's immunomodulatory activity.
Water-soluble polysaccharides associated with immune-stimulating activity, particularly from the aerial parts.
The volatile oil, dominated by thymol and carvacrol, gives most of the antimicrobial and antioxidant activity.
Contribute additional antioxidant activity.
Minor constituents studied for anti-inflammatory activity.
Pharmacological Actions
Traditional & Indicated Uses
inferred from anti-inflammatory action
inferred from immunomodulator action
inferred from antimicrobial action
inferred from anti-inflammatory action
inferred from anti-inflammatory action
inferred from gastroprotective action
inferred from anti-inflammatory action
inferred from anticancer action
inferred from gastroprotective action
inferred from antimicrobial action
inferred from anti-inflammatory action
inferred from anti-inflammatory action
Safety, Cautions & Contraindications
Generally considered safe, but caution advised for those with autoimmune conditions. Not recommended for long-term use (more than 8 weeks continuously).
Duke (2002) rates echinacea as +++ — among the most thoroughly documented herbal immunostimulants. It notes experimental and clinical evidence for immunostimulant, antiviral, and anti-inflammatory activities. Multiple species have been studied (E. purpurea, E. angustifolia, E. pallida), and Duke emphasizes that species identification in commercial products is often unreliable. Commission E approves E. purpurea for supporting immune function during colds and flu. Dose: 900 mg standardized extract daily in acute use; use should be limited to 8 weeks continuous. Contraindicated in autoimmune diseases (MS, lupus, HIV/AIDS), tuberculosis, and with immunosuppressive drugs (cyclosporine) (Duke, 2002).
Generally safe at culinary doses. Essential oil is highly concentrated and must be diluted before topical use; undiluted application can cause skin sensitisation. Not recommended internally during pregnancy (uterine stimulant effects possible). Phenol-rich thyme preparations should be avoided long-term in high doses. May potentiate anticoagulant medications.
Duke (2002) rates Thymus vulgaris (garden thyme, closely related to breckland thyme) as +++ with clinical evidence (score 2) for antibacterial, bronchospasmolytic, and antispasmodic activities, consistent with Commission E and WHO approvals for bronchitis and upper respiratory catarrh. The primary active constituent is thymol, with carvacrol as a secondary compound. Dose: 1–2 g dried herb as tea three times daily. The plant demonstrates COX-2 inhibitory activity and calcium antagonism, which may explain its antispasmodic effects (Duke, 2002).
External Ids
Botanical Description
Robust perennial herb with a basal rosette of coarse, hairy, lance-shaped leaves and tall, sturdy flowering stems. Each stem bears a single large, daisy-like flower head with drooping (reflexed), rose-purple to pink ray florets surrounding a prominent, spiny, orange-brown central cone of disc florets.[4]
Low, mat-forming, aromatic perennial subshrub with tiny, oval, strongly aromatic leaves on trailing, wiry, hairy stems that root as they spread. Small, pinkish-purple, two-lipped flowers are borne in dense whorled clusters at the stem tips.
Habitat
Native to the tallgrass prairies, open woodland and dry meadows of central and eastern North America; widely cultivated worldwide as a garden and medicinal plant.[4]
Grows on dry, sunny heath, grassland, rocky ground and sandy soils; native to Europe and widely distributed across the northern temperate zone.
Harvesting
The flower heads are picked as they open, in summer; the root is dug in autumn from plants at least two to three years old, when its content of bioactive alkamides and caffeic acid derivatives is highest, then cleaned and dried.[4]
The flowering aerial parts (flower and leaf) are cut at the start of flowering in summer and dried in a warm, shaded, airy place.
Traditional Uses
Echinacea root was widely used by Native American peoples as a remedy for infections, wounds, snakebite and toothache, and entered nineteenth-century Eclectic medicine as a broad anti-infective. It remains best known today, in standardised aerial-part or root extracts, as a supportive remedy for preventing and shortening the common cold and supporting immune function.[1, 4]
Preparations
Dosage
Clinical trials for the common cold commonly use around 300-900 mg of standardised extract daily, started at the first sign of symptoms and continued for up to 7-10 days; continuous use beyond about 8 weeks is not recommended. Educational reference only, not a prescription.
Not documented
References
Drug Class Interactions
Not documented
Lookalikes Review
References & Sources
- Karsch-Völk, M., Barrett, B., Kiefer, D., Bauer, R. et al (2014) 'Echinacea for preventing and treating the common cold', Cochrane Database of Systematic Reviews, 2(2), pp. CD000530. doi:10.1002/14651858.CD000530.pub3 Meta-analysis / review
https://doi.org/10.1002/14651858.CD000530.pub3 - Kamin, W., Seifert, G., Zwiauer, K., Bonhoeffer, J. et al (2025) 'Phytotherapy for acute respiratory tract infections in children: a systematically conducted, comprehensive review', Frontiers in Pediatrics, 13, pp. 1423250. doi:10.3389/fped.2025.1423250 Meta-analysis / review
https://doi.org/10.3389/fped.2025.1423250 - Fashner, J., Ericson, K. and Werner, S (2012) 'Treatment of the common cold in children and adults', American Family Physician, 86(2), pp. 153-159. Available at: https://pubmed.ncbi.nlm.nih.gov/22962927/ Traditional / reference
https://pubmed.ncbi.nlm.nih.gov/22962927/ - Manayi, A., Vazirian, M. and Saeidnia, S (2015) 'Echinacea purpurea: Pharmacology, phytochemistry and analysis methods', Pharmacognosy Reviews, 9(17), pp. 63-72. doi:10.4103/0973-7847.156353 Meta-analysis / review
https://doi.org/10.4103/0973-7847.156353 - Burlou-Nagy, C., Banica, F., Jurca, T., Vicas, L.G., Marian, E., Muresan, M.E., Bacskay, I., Kiss, R., Feher, P. and Pallag, A (2022) 'Echinacea purpurea (L.) Moench: Biological and Pharmacological Properties. A Review', Plants, 11(9), pp. 1244. doi:10.3390/plants11091244 Meta-analysis / review
https://doi.org/10.3390/plants11091244 - Hall, H., Fahlman, M.M. and Engels, H.J (2007) 'Echinacea purpurea and mucosal immunity', International Journal of Sports Medicine, 28(9), pp. 792-797. doi:10.1055/s-2007-964895 Randomized trial
https://doi.org/10.1055/s-2007-964895 - Ross, S.M (2016) 'Echinacea purpurea: A Proprietary Extract of Echinacea purpurea Is Shown to be Safe and Effective in the Prevention of the Common Cold', Holistic Nursing Practice, 30(1), pp. 54-57. doi:10.1097/HNP.0000000000000130 Meta-analysis / review
https://doi.org/10.1097/HNP.0000000000000130 - Hudson, J.B (2011) 'Applications of the phytomedicine Echinacea purpurea (Purple Coneflower) in infectious diseases', Journal of Biomedicine & Biotechnology, 2012, pp. 769896. doi:10.1155/2012/769896 Meta-analysis / review
https://doi.org/10.1155/2012/769896 - Mishima, S., Saito, K., Maruyama, H., Inoue, M., Yamashita, T., Ishida, T. and Gu, Y (2004) 'Antioxidant and immuno-enhancing effects of Echinacea purpurea', Biological & Pharmaceutical Bulletin, 27(7), pp. 1004-1009. doi:10.1248/bpb.27.1004 Preclinical
https://doi.org/10.1248/bpb.27.1004 - Saunders, P.R., Smith, F. and Schusky, R.W (2007) 'Echinacea purpurea L. in children: safety, tolerability, compliance, and clinical effectiveness in upper respiratory tract infections', Canadian Journal of Physiology and Pharmacology, 85(11), pp. 1195-1199. doi:10.1139/Y07-103 Clinical study
https://doi.org/10.1139/Y07-103 - Micheli, L., Maggini, V., Ciampi, C., Gallo, E., Bogani, P., Fani, R., Pistelli, L., Ghelardini, C., Di Cesare Mannelli, L., De Leo, M. and Firenzuoli, F (2022) 'Echinacea purpurea against neuropathic pain: Alkamides versus polyphenols efficacy', Phytotherapy Research, 37(5), pp. 1911-1923. doi:10.1002/ptr.7709 Preclinical
https://doi.org/10.1002/ptr.7709 - Gholami, M., Amri, J., Pazhoohan, S. and Sadegh, M (2021) 'Anticonvulsive and anti-epileptogenesis effects of Echinacea purpurea root extract, an involvement of CB2 receptor', Journal of Complementary & Integrative Medicine, 19(4), pp. 879-886. doi:10.1515/jcim-2020-0219 Preclinical
https://doi.org/10.1515/jcim-2020-0219 - Awortwe, C., Bruckmueller, H., Kaehler, M. and Cascorbi, I (2021) 'Interaction of Phytocompounds of Echinacea purpurea with ABCB1 and ABCG2 Efflux Transporters', Molecular Pharmaceutics, 18(4), pp. 1622-1633. doi:10.1021/acs.molpharmaceut.0c01075 Preclinical
https://doi.org/10.1021/acs.molpharmaceut.0c01075 - Perry, N.B., van Klink, J.W., Burgess, E.J. and Parmenter, G.A (1997) 'Alkamide levels in Echinacea purpurea: a rapid analytical method revealing differences among roots, rhizomes, stems, leaves and flowers', Planta Medica, 63(1), pp. 58-62. doi:10.1055/s-2006-957605 Preclinical
https://doi.org/10.1055/s-2006-957605 - Linde, K., Barrett, B., Wölkart, K., Bauer, R. and Melchart, D (2006) 'Echinacea for preventing and treating the common cold'. Traditional / reference
https://scholar.google.com/scholar?q=Echinacea%20for%20preventing%20and%20treating%20the%20common%20cold - Sharma, M., Schoop, R., Suter, A. and Schoop, W (2010) 'The possibility of prophylactic treatment of streptococcal pharyngotonsillitis with a standardized Echinacea preparation', 29(8), pp. 1025--1035. Traditional / reference
https://scholar.google.com/scholar?q=The%20possibility%20of%20prophylactic%20treatment%20of%20streptococcal%20pharyngotonsillitis%20with%20a%20standardized%20Echinacea%20preparation - World Health Organization (1999) 'WHO Monographs on Selected Medicinal Plants'. Traditional / reference
https://scholar.google.com/scholar?q=WHO%20Monographs%20on%20Selected%20Medicinal%20Plants - Duke, J.A (2002) 'Handbook of Medicinal Herbs, Second Edition'. Traditional / reference
https://scholar.google.com/scholar?q=Handbook%20of%20Medicinal%20Herbs%2C%20Second%20Edition - Gorski, J.C., Huang, S.M., Pinto, A., Hamman, M.A., Hilligoss, J.K., Zaheer, N.A., Desai, M., Miller, M. and Hall, S.D (2004) 'The effect of echinacea (Echinacea purpurea root) on cytochrome P450 activity in vivo', Clinical Pharmacology and Therapeutics, 75(1), pp. 89-100. doi:10.1016/j.clpt.2003.09.013 Clinical study
https://doi.org/10.1016/j.clpt.2003.09.013
- Jalil, B., Pischel, I., Feistel, B., Suarez, C. and others (2024) 'Wild thyme (Thymus serpyllum L.): a review of the current evidence of nutritional and preventive health benefits', Frontiers in Nutrition, 11, pp. 1380962. doi:10.3389/fnut.2024.1380962 Meta-analysis / review
https://doi.org/10.3389/fnut.2024.1380962 - Sonmezdag, A.S., Kelebek, H. and Selli, S (2016) 'Characterization of aroma-active and phenolic profiles of wild thyme (Thymus serpyllum) by GC-MS-Olfactometry and LC-ESI-MS/MS', Journal of Food Science and Technology, 53(4), pp. 1957-1965. doi:10.1007/s13197-015-2144-1 Preclinical
https://doi.org/10.1007/s13197-015-2144-1 - Pavlic, B., Mrkonjic, Z., Teslic, N., Kljakic, A.C. and others (2022) 'Natural Deep Eutectic Solvent (NADES) Extraction Improves Polyphenol Yield and Antioxidant Activity of Wild Thyme (Thymus serpyllum L.) Extracts', Molecules, 27(5), pp. 1508. doi:10.3390/molecules27051508 Preclinical
https://doi.org/10.3390/molecules27051508 - Mrkonjic, Z., Kaplan, M., Milosevic, S., Bozovic, D. and others (2024) 'Green Extraction Approach for Isolation of Bioactive Compounds in Wild Thyme (Thymus serpyllum L.) Herbal Dust-Chemical Profile, Antioxidant and Antimicrobial Activity and Comparison with Conventional Techniques', Plants, 13(6), pp. 897. doi:10.3390/plants13060897 Preclinical
https://doi.org/10.3390/plants13060897 - Sokolic-Mihalak, D., Frece, J., Slavica, A., Delas, F. and others (2012) 'The effects of wild thyme (Thymus serpyllum L.) essential oil components against ochratoxin-producing Aspergilli', Arhiv za Higijenu Rada i Toksikologiju, 63(4), pp. 457-462. doi:10.2478/10004-1254-63-2012-2309 Preclinical
https://doi.org/10.2478/10004-1254-63-2012-2309 - Jaric, S., Mitrovic, M. and Pavlovic, P (2015) 'Review of Ethnobotanical, Phytochemical, and Pharmacological Study of Thymus serpyllum L', Evidence-Based Complementary and Alternative Medicine, 2015, pp. 101978. doi:10.1155/2015/101978 Meta-analysis / review
https://doi.org/10.1155/2015/101978 - Loziene, K., Vaiciuniene, J. and Venskutonis, P.R (1998) 'Chemical composition of the essential oil of creeping thyme (Thymus serpyllum s.l.) growing wild in Lithuania', Planta Medica, 64(8), pp. 772-773. doi:10.1055/s-2006-957582 Preclinical
https://doi.org/10.1055/s-2006-957582 - Raal, A., Paaver, U., Arak, E. and Orav, A (2004) 'Content and composition of the essential oil of Thymus serpyllum L. growing wild in Estonia', Medicina (Kaunas), 40(8), pp. 795-800. Preclinical
https://scholar.google.com/scholar?q=Content%20and%20composition%20of%20the%20essential%20oil%20of%20Thymus%20serpyllum%20L.%20growing%20wild%20in%20Estonia - Bozkurt, E., Atmaca, H., Kisim, A., Uzunoglu, S. and others (2012) 'Effects of Thymus serpyllum extract on cell proliferation, apoptosis and epigenetic events in human breast cancer cells', Nutrition and Cancer, 64(8), pp. 1245-1250. doi:10.1080/01635581.2012.719658 Preclinical
https://doi.org/10.1080/01635581.2012.719658 - Jovanovic, A.A., Levic, S.M., Pavlovic, V.B., Markovic, S.B. and others (2021) 'Freeze vs. Spray Drying for Dry Wild Thyme (Thymus serpyllum L.) Extract Formulations: The Impact of Gelatin as a Coating Material', Molecules, 26(13), pp. 3933. doi:10.3390/molecules26133933 Preclinical
https://doi.org/10.3390/molecules26133933 - European Medicines Agency (2010) 'Assessment report on Thymus vulgaris L., herba and Thymus zygis L., herba'. Traditional / reference
https://scholar.google.com/scholar?q=Assessment%20report%20on%20Thymus%20vulgaris%20L.%2C%20herba%20and%20Thymus%20zygis%20L.%2C%20herba - Kempe, K., Doerfler, G., Bader, D. and Wicht, M (2011) 'Activity of Thymus serpyllum against oral pathogens', 9(1), pp. 23--28. Traditional / reference
https://scholar.google.com/scholar?q=Activity%20of%20Thymus%20serpyllum%20against%20oral%20pathogens - Royal Botanic Gardens, Kew (n.d.). Available at: https://powo.science.kew.org Traditional / reference
https://powo.science.kew.org - Duke, J.A (2002) 'Handbook of Medicinal Herbs, Second Edition'. Traditional / reference
https://scholar.google.com/scholar?q=Handbook%20of%20Medicinal%20Herbs%2C%20Second%20Edition
Generated automatically from the Omnia Sana plant database and its cited sources. For educational purposes only — not medical advice. Always consult a qualified practitioner before using medicinal plants.